The DOI matches its Crossref record; 349 of the 363 references it cites were found in a registry or an index; 20 of the 40 sources its claims cite were checked for support.
Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation.
Open accessAbstract
Updated ISHLT consensus providing a framework for identifying candidates for lung transplantation and accounting for combinations of risk factors in candidacy selection.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
9 Partly supported · 6 No basis given · 4 Couldn’t confirm · 3 Own method · 1 Supported · 1 Sources not found · 1 No full text of the sources · accuracy not yet measured
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The ESC/ERS model also employs the assessment of risk using a multi-parametric comprehensive analysis of clinical variables.(284) Unlike REVEAL, this model avoids use of any non-modifiable criteria, and does not “weight” the variables according to their relative importance.”
§ Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation > DISEASE SPECIFIC CONSIDERATIONS > PULMONARY ARTERIAL HYPERTENSION (PAH)
What the sources say
- Partly supportedcites [284] Galiè, 2016, Eur Heart J sourceExperimental — accuracy not yet measured
Section 6.2.4 calls for a multidimensional, comprehensive assessment, and section 6.2.5 says overall assessment should guide decisions when variables fall into different risk categories. The claim that the model avoids any nonmodifiable criteria is too absolute: both sections say age, sex, and other factors not affected by therapy can modify risk. The passages do not explicitly specify whether variables receive numerical weights. (LLM, conf=0.85)
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“This trend reflects the expansion of acceptable donors and candidates made possible by clinical and scientific advances. Far fewer absolute contraindications for lung transplant candidacy exist now, compared to the time of publication of prior versions of this document, making the selection of candidates even more complex.”
§ Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation > INTRODUCTION:
What the sources say
- Partly supportedcites [2] Orens, 2006, International guidelines for the selection of lung transplant candidates: 2006 update—a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation, J Heart Lung Transplant sourceExperimental — accuracy not yet measured
The introduction says advances in technology and medical knowledge prompted updated candidate-selection guidelines, and the Relative contraindications section allows consideration of some candidates previously treated more restrictively. But our copy does not state that lung transplantation expanded worldwide because more donors became acceptable, nor does it explicitly say there are far fewer absolute contraindications than in 1998 or that selection has become more complex for that reason. No page numbers are available in our copy. (LLM, conf=0.83)
- Not checked — no full text of the sourcecites [3] Maurer, 1998, International guidelines for the selection of lung transplant candidates, Transplantation source
- Not checked — no full text of the sourcecites [4] Weill, 2015, A consensus document for the selection of lung transplant candidates: 2014–an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation, J Heart Lung Transplant source
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Frailty, defined as a generalized vulnerability to stressors resulting from the presence of multiple physiologic deficits, is associated with an increased risk of waitlist and post-transplant mortality.(51–53) However, frailty in lung transplant candidates is often attributable to advanced lung disease and may improve following transplant.”
§ Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation > RISK FACTORS TO BE CONSIDERED: > Functional Status and Frailty:
What the sources say
- Partly supportedcites [51] Baldwin, 2017, Refining low physical activity measurement improves frailty assessment in advanced lung disease and survivors of critical illness, Ann Am Thorac Soc sourceExperimental — accuracy not yet measured
The Results (page unavailable) link frailty measured with FFP-DASI to increased death or delisting among lung-transplant candidates. The Methods (page unavailable) say participants were censored at transplant, so this study does not support the post-transplant mortality claim. The Abstract says no gold-standard frailty measure exists, but the paper does not specifically address using frailty measures for listing decisions. (LLM, conf=0.90)
- Supportedcites [52] Singer, 2018, Frailty phenotypes and mortality after lung transplantation: a prospective cohort study, Am J Transplant source
The Discussion states that frailty is associated with both waitlist and post-transplant mortality. It also says further work is needed to identify valid frailty measures before using them in organ allocation; the available passages do not give page numbers. (LLM, conf=0.93)
- Not checked — no full text of the sourcecites [53] Singer, 2015, Frailty phenotypes, disability, and outcomes in adult candidates for lung transplantation, Am J Respir Crit Care Med source
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Despite improved overall outcomes, many individuals with advanced CF lung disease remain at risk of short-term mortality. A 2017 study demonstrated a 10% risk of death each year after reaching an FEV1 < 30%, with many patients dying soon after reaching this threshold.”
§ Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation > DISEASE SPECIFIC CONSIDERATIONS > CYSTIC FIBROSIS
What the sources say
- Supportedcites [245] Ramos, 2017, Heterogeneity in survival in adult patients with cystic fibrosis with FEV1 < 30% of predicted in the United States, Chest source
The Discussion reports improved survival but an approximately 10% annual probability of death once FEV1 falls below 30% predicted. The Conclusions add that some patients die soon after reaching that threshold, while others live for many years. (LLM, conf=0.92)
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Lung transplant candidates must demonstrate abstinence from use of all tobacco and nicotine products (including nicotine replacement therapy) prior to transplant (e.g. with serial nicotine and cotinine screening).(111)”
§ Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation > PSYCHOSOCIAL RISK FACTORS: > Nicotine:
What the sources say
- Partly supportedcites [111] Hofmann, 2018, Smoking resumption after heart or lung transplantation: a systematic review and suggestions for screening and management, J Thorac Dis sourceExperimental — accuracy not yet measured
The Introduction says candidates are normally required to be smoke-free before joining a thoracic-transplant waiting list. But the systematic-screening section recommends cotinine testing at post-transplant follow-ups, not serial nicotine and cotinine testing before transplant. The paper also says nicotine replacement therapy can be used in transplant recipients; it does not establish the claimed pre-transplant ban on all nicotine products. (LLM, conf=0.88)
- Partly supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Non-CF bronchiectasis represents 2.7% of all lung transplants reported to the ISHLT Registry between 1995–2018.”
§ Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation > DISEASE SPECIFIC CONSIDERATIONS > NON-CYSTIC FIBROSIS BRONCHIECTASIS
What the sources say
- Could not verifycites [1] Chambers, 2019, The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-sixth adult lung and heart–lung transplantation Report—2019; Focus theme: donor and recipient size match, J Heart Lung Transplant sourceExperimental — accuracy not yet measured
The Lung transplantation—Indications section says Table 1 covers transplant indications since January 1995, but the passages available from our copy do not give a figure for non-CF bronchiectasis. Searches for “non-CF bronchiectasis,” “bronchiectasis,” and “2.7%” did not find the claimed proportion; the quoted passages instead discuss other indications and bronchiolitis obliterans syndrome. (LLM, conf=0.70)
- Could not verify
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Lung transplant for LAM is relatively rare; however, it is associated with better post-transplant survival compared to other advanced lung diseases.(1, 303–307)”
§ Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation > DISEASE SPECIFIC CONSIDERATIONS > LYMPHANGIOLEIOMYOMATOSIS (LAM)
What the sources say
- Partly supportedcites [1] Chambers, 2019, The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-sixth adult lung and heart–lung transplantation Report—2019; Focus theme: donor and recipient size match, J Heart Lung Transplant sourceExperimental — accuracy not yet measured
The Lung transplantation section (page unavailable) reports that lymphangioleiomyomatosis as an indication for transplantation is favorably associated with survival in a multivariable model. It does not establish that LAM transplantation is relatively rare or recommend bilateral transplantation when organs are available; its favorable association for bilateral transplantation is reported separately, not specifically for LAM. (LLM, conf=0.87)
- Supportedcites [303] Ando, 2016, Lung Transplantation for lymphangioleiomyomatosis in Japan, PLoS One source
The Introduction describes LAM as rare and says it accounted for about 1% of heart or lung transplantation indications in an international survey. The Discussion reports that the Japanese LAM recipients had more favorable post-transplant survival than patients transplanted for other indications. The printed citing sentence does not make a claim about bilateral transplantation. (LLM, conf=0.92)
- Not checked — no full text of the sourcecites [304] Khawar, 2019, Clinical outcomes and survival following lung transplantation in patients with lymphangioleiomyomatosis, J Heart Lung Transplant source
- Not checked — no full text of the sourcecites [305] Baldi, 2017, Experience of lung transplantation in patients with lymphangioleiomyomatosis at a Brazilian reference centre, Lung source
- Not checked — no full text of the sourcecites [306] Kurosaki, 2020, Favorable survival even with high disease-specific complication rates in lymphangioleiomyomatosis after lung transplantation-long-term follow-up of a Japanese center, Clin Respir J source
- Not checked — no full text of the sourcecites [307] Kpodonu, 2005, The US experience with lung transplantation for pulmonary lymphangioleiomyomatosis, J Heart Lung Transplant source
- Partly supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“An updated version of the score, REVEAL 2.0, which incorporates estimated GFR and all-cause hospitalizations within the previous six-months, has emerged as a powerful predictor of mortality and clinical worsening.(285–287) Neither of the REVEAL scores has been validated prospectively.”
§ Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation > DISEASE SPECIFIC CONSIDERATIONS > PULMONARY ARTERIAL HYPERTENSION (PAH)
What the sources say
- Not checked — no full text of the sourcecites [285] Benza, 2019, Predicting survival in patients with pulmonary arterial hypertension: The REVEAL Risk Score Calculator 2.0 and comparison with ESC/ERS-Based risk assessment strategies, Chest source
- Could not verifycites [286] Chakinala, 2018, Impact of declining renal function on outcomes in pulmonary arterial hypertension: a REVEAL registry analysis, J Heart Lung Transplant sourceExperimental — accuracy not yet measured
The Discussion describes renal insufficiency as a mortality predictor included in the REVEAL risk score, and the Statistical analysis uses that score for adjustment. Our copy does not address REVEAL 2.0’s predictive performance or prospective validation (searched: REVEAL 2.0, clinical worsening, prospective validation). (LLM, conf=0.75)
- Not checked — no full text of the sourcecites [287] Frost, 2013, Evaluation of the predictive value of a clinical worsening definition using 2-year outcomes in patients with pulmonary arterial hypertension: a REVEAL Registry analysis, Chest source
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Lung volume reduction (LVR), performed by either surgical or bronchoscopic approach, is an option for a subset of COPD patients with advanced emphysema who meet strict selection criteria. These procedures have been associated with improved lung function, exercise capacity, and quality of life.(181–183)”
§ Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation > DISEASE SPECIFIC CONSIDERATIONS > CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
What the sources say
- Partly supportedcites [181] Criner, 2019, Improving lung function in severe heterogenous emphysema with the spiration valve system (EMPROVE). A multicenter, open-label randomized controlled clinical trial, Am J Respir Crit Care Med sourceExperimental — accuracy not yet measured
The Scientific Knowledge commentary says lung volume reduction surgery can improve lung function but is limited to eligible patients; the Results report improved lung function and health status after bronchoscopic valve treatment. The Results also say the improvement in exercise capacity was not statistically significant. The claim’s reference to delaying transplant is absent from the verbatim citing sentence and is not established by these passages. (LLM, conf=0.87)
- Partly supportedcites [182] Criner, 2018, A multicenter randomized controlled trial of Zephyr Endobronchial valve treatment in heterogeneous emphysema (LIBERATE), Am J Respir Crit Care Med sourceExperimental — accuracy not yet measured
The Introduction and Conclusion (pages not provided) describe surgical and bronchoscopic lung volume reduction as options for carefully selected patients with severe emphysema. The Discussion reports improvements in lung function, exercise capacity, and quality of life. The copy does not say these treatments delay transplantation; that point also does not appear in the verbatim citing sentence. (LLM, conf=0.85)
- Partly supportedcites [183] Fishman, 2003, A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema, N Engl J Med sourceExperimental — accuracy not yet measured
The Discussion (p. 2071) reports that lung-volume-reduction surgery increased the chance of improved exercise capacity, lung function, and quality of life, with benefits varying by patient subgroup. The Methods (page not supplied) describe surgical approaches, not bronchoscopic reduction, so this paper does not support the sentence’s extension to both approaches. The citing sentence does not make a transplant-delay claim; the Treatment section reports transplant counts but does not establish that surgery delayed transplantation. (LLM, conf=0.87)
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The BODE index [BMI, airflow limitation (forced expiratory volume in one second), dyspnea and 6-min walk distance], which has been externally validated in at least 13 additional cohorts following the original derivation. The BODE index has been cited as the prognostic model of choice by the Global Initiative for Chronic Obstructive Lung Disease (GOLD), and it formed the basis for listing recommendations in the 2014 ISHLT candidate selection guidelines. (4, 166–168)”
§ Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation > DISEASE SPECIFIC CONSIDERATIONS > CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
What the sources say
- Not checked — no full text of the sourcecites [4] Weill, 2015, A consensus document for the selection of lung transplant candidates: 2014–an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation, J Heart Lung Transplant source
- Not checked — no full text of the sourcecites [166] Celli, 2004, The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease, N Engl J Med source
- Partly supportedcites [167] Bellou, 2019, Prognostic models for outcome prediction in patients with chronic obstructive pulmonary disease: systematic review and critical appraisal, BMJ sourceExperimental — accuracy not yet measured
The external validation studies section reports that BODE was externally validated in 13 cohorts. The Principal findings in context section says GOLD uses BODE in clinical decision-making for lung transplantation, but our copy does not say that BODE formed the basis of the 2014 ISHLT listing recommendations. (LLM, conf=0.88)
- Not matchedcites [168] Disease GIfCOL: Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease: 2020 Report. 2020.
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Active infections are generally contraindications for transplantation.”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In cases of CF and non-CF bronchiectasis, the colonization of resistant bacteria progresses, thereby increasing mortality after surgery.”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although COPD remains the most common indication for lung transplantation”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“transplantation is possible despite infections with non-tuberculous mycobacteria, non-aspergillus molds, and Burkholderia cepacia complex if accompanied by appropriate treatment [3,26-28].”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the BODE score (body mass index, degree of airway obstruction, dyspnea, and exercise capacity score) is still the most important indicator, and along with it, FEV1 and the presence or absence of acute exacerbation determine whether transplantation is possible based on the presence or absence of evidence for pulmonary arterial hypertension (PAH), as summarized in Table 2 [3,42].”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [3]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The current consensus is based on 2 tools for referral and listing: the REVEAL Registry 2.2 (Registry to Evaluate Early and Long-term Pulmonary Arterial Hypertension Disease Management 2.0) and 2015 European Society of Cardiology/European Respiratory Society.”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Group 2, with decreased left ventricular function, is not an indication for transplantation”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the World Symposium of Pulmonary Hypertension classification of PAH, group 1 is the most common indication.”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“transplantation may be necessary if prostacyclin treatment is required for an appropriate intervention, there is accompanying liver or renal failure, or severe hemoptysis is present [3,59-62]”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [3]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In 2021, the International Society for Heart and Lung Transplantation (ISHLT) published a new consensus document for selecting candidates for lung transplantation [3].”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [3]
The cited source says what the claim attributes to it.
In the citing paper
“group 3 with PAH and accompanying pathological changes in the lung parenchyma can be considered for transplantation.”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [3]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The use of immunosuppressive drugs after transplantation may lead to poor control of infection and progression to sepsis.”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [3]
Experimental — accuracy not yet measured
Citations
Cites
Principles of Biomedical Ethics
(2012) · Thieves of Virtue · doi:10.7551/mitpress/9079.003.0009 · Cited by 13,453
Chen, Y., Wang, L., Kang, Q., Zhang, X., Yu, G., Wan, X., Wang, J., & Zhu, K. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000477308 · Cited by 10,730
Acute Respiratory Distress Syndrome
Ards Definition Task Force (2012) · JAMA · doi:10.1001/jama.2012.5669 · Cited by 9,066
2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
Galiè, N., Humbert, M., Vachiery, J.-L., Gibbs, S., Lang, I., Torbicki, A., Simonneau, G., Peacock, A., Vonk Noordegraaf, A., Beghetti, M., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv317 · Cited by 6,931
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402584 · Cited by 4,654
Celli, B. R., Cote, C. G., Marin, J. M., Casanova, C., Montes de Oca, M., Mendez, R. A., Pinto Plata, V., & Cabral, H. J. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa021322 · Cited by 4,015
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402582 · Cited by 3,975
Haemodynamic definitions and updated clinical classification of pulmonary hypertension
Simonneau, G., Montani, D., Celermajer, D. S., Denton, C. P., Gatzoulis, M. A., Krowka, M., Williams, P. G., & Souza, R. (2019) · European Respiratory Journal · doi:10.1183/13993003.01913-2018 · Cited by 3,813
Nintedanib in Progressive Fibrosing Interstitial Lung Diseases
Flaherty, K. R., Wells, A. U., Cottin, V., Devaraj, A., Walsh, S. L. F., Inoue, Y., Richeldi, L., Kolb, M., Tetzlaff, K., Stowasser, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1908681 · Cited by 2,403
A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema
(2003) · New England Journal of Medicine · doi:10.1056/nejmoa030287 · Cited by 2,071 · cited 2×
“…benefit has been demonstrated in a select group of patients with upper lobe predominant emphysema and low exercise capacity who undergo surgical LVR. 183 184-187 Prior LVR surgery can lead to formation of pleural adhesions, which can pose technical challenges to the surgeon at the time of…”
Background
Research works printed but not linked: 1
- Kulig, 2017, Interpretation of workplace tests for cannabinoids, J Med Toxicol, 13, 106, 10.1007/s13181-016-0587-z · DOI · Paper page
Cited by
Sorted by citations
Items 201–300 of 798
Jones-Pauley, M., Kodali, S., Basra, T., & Victor, D. W. (2023) · World Journal of Transplantation · doi:10.5500/wjt.v13.i4.129 · Cited by 7
Management of Pulmonary Arterial Hypertension
Weatherald, J. C., Varughese, R. A., Liu, J., & Humbert, M. J. C. (2023) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0043-1770118 · Cited by 7
Gabryel, P., Skrzypczak, P. J., Campisi, A., et al. (2023) · Cancers · doi:10.3390/cancers15153877 · Cited by 6
“Lung transplantation is an effective treatment for advanced COPD, but it is absolutely contraindicated for lung cancer [44].”
BackgroundAhmed, H. F., Guzman‐Gomez, A., Desai, M. V., et al. (2023) · Pediatric Cardiology · doi:10.1007/s00246-023-03356-x · Cited by 6
Opportunistic Infections Post-Lung Transplantation: Viral, Fungal, and Mycobacterial
Magda, G. (2024) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2023.12.001 · Cited by 6
Bottiger, B., Klapper, J. A., Fessler, J., Shaz, B. H., & Levy, J. H. (2024) · Anesthesiology · doi:10.1097/aln.0000000000004829 · Cited by 6
“33 Further, they recommend extreme caution in considering the transplantation of recipients carrying excessively high risk for complications, including bleeding diathesis, thrombophilia, and bone marrow dysfunction, because of the challenges in managing bleeding during the procedure.”
BackgroundThe Relationship Between Rehabilitation and Frailty in Advanced Heart or Lung Disease
Dinesh, V., Pierce, R., Hespe, L., Thakkar, S., Wong, M. A., Sabbagh, L. E., Honeysett, L., Brown, P., Delbaere, K., Havryk, A. P., et al. (2024) · Transplantation Direct · doi:10.1097/txd.0000000000001606 · Cited by 7
Dsouza, K. G., Alexander, A. S., Watts, J. R., & Kulkarni, T. (2023) · Multidisciplinary Respiratory Medicine · doi:10.4081/mrm.2023.890 · Cited by 10
“For patients who progress despite pharmacological therapy, lung transplant should be considered [42].”
BackgroundKolaitis, N. A., Singer, J. P., Bartolome, S., Chakinala, M. M., Grinnan, D., Hemnes, A. R., Heresi, G. A., Leary, P. J., Shlobin, O. A., Ventetuolo, C. E., et al. (2025) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2025.06.019 · Cited by 5
Self-citationPharmacotherapy for Autoimmune Pulmonary Alveolar Proteinosis
Jouneau, S., Chauvin, P., Léderlin, M., et al. (2025) · Drugs · doi:10.1007/s40265-025-02228-3 · Cited by 5
“…may be considered for aPAP, as for other chronic respiratory diseases, for those with end-stage irreversible pulmonary fibrosis in addition to terminal respiratory failure despite optimal medical treatment, and in the absence of absolute contraindications to lung transplantation [53–55].”
Zajacová, A., Dupont, L., Leyn, P. D., Ceulemans, L. J., Vos, R., & Leuven Lung Transplant Group (2025) · Transplant International · doi:10.3389/ti.2025.15495 · Cited by 6
“This is in line with evolving ISHLT candidate selection recommendations: in 2014, age > 65 years was a relative contraindication, while in 2021, age 65 – 70 years became a risk factor only [6, 7].”
Deri, O., Ovadia, D., Huszti, E., Peled, M., Saute, M., Hod, T., Onn, A., Seluk, L., Furie, N., Shafran, I. H., et al. (2024) · Therapeutic Advances in Respiratory Disease · doi:10.1177/17534666231221750 · Cited by 7
“9,10 It is worth highlighting that in Israel there was no age limitation to LTx at the time of the study, and the lung allocation score 17 was used to prioritize candidates on the waitlist.”
BackgroundPradère, P., Pavec, J. L., Bos, S., Pozza, A., Nair, A., Meachery, G. J., Lordan, J. L., Humbert, M. J. C., Mercier, O. M., Fadel, É., et al. (2024) · ERJ Open Research · doi:10.1183/23120541.00521-2023 · Cited by 5
“…Heart and Lung Transplantation (ISHLT) stated indeed that “ new contemporary multimodal risk stratification tools, which outperform individual predictors of disease progression, combined with other pertinent clinical information, should be used to guide timing of referral and listing for LT ” [24].”
BackgroundImpact of bridging veno-venous extracorporeal membrane oxygenation to COVID-19 lung transplantation
Toyoda, T., Thomae, B. L., Kaiho, T., Cerier, E. J., Tomic, R., Budinger, G. R. S., Bharat, A., & Kurihara, C. (2024) · Journal of Thoracic Disease · doi:10.21037/jtd-24-132 · Cited by 6
Pediatric lung transplantation for childhood interstitial lung disease: Indications and outcome
Schneider, H., Ius, F., Müller, C., Salman, J., Schütz, K., Köditz, H., Nickel, K., Hansen, G., Bobylev, D., Schwerk, N., et al. (2025) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2025.04.001 · Cited by 6
Zajacova, A., Alkhouri, M., Ferrão, G., et al. (2025) · Transplant Immunology · doi:10.1016/j.trim.2025.102245 · Cited by 5
Solid organ transplantation in people with HIV : Outcomes, obstacles and opportunities
Griffin, D. W. J., McMahon, J. H., Ruschena, D. A., & Hoy, J. (2025) · HIV Medicine · doi:10.1111/hiv.70099 · Cited by 5
“…HIV as ‘ ruling-out ’ or ‘ contraindicating ’ donation and SOT and uses risk-based and stigmatizing language, though some acknowledge the use of conservative estimates around the likelihood of HIV transmission, disregarding the high effectiveness of biomedical prevention modalities [82, 133 – 136].”
A center experience with lung transplantation for COVID-19 ARDS
Franco‐Palacios, D. J., Allenspach, L. L., Stagner, L. D., Pinto, J., OLEXSEY, K. H., Sherbin, E., Dillon, W. J., Sternberg, D., Bryce, K., Simanovski, J., et al. (2022) · Respiratory Medicine Case Reports · doi:10.1016/j.rmcr.2022.101597 · Cited by 6
Emsley, C., Snell, G. I., Paul, E. M., Fuller, L., Paraskeva, M. A., Nyulasi, I. B., & King, S. (2022) · Clinical Transplantation · doi:10.1111/ctr.14763 · Cited by 5
Current Challenges and Advances in Organ Donation and Transplantation
Tsoulfas, G. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.102229 · Cited by 5
Tanaka, S., de Tymowski, C., Tran‐Dinh, A., Meilhac, O., Lortat‐Jacob, B., Zappella, N., Jean‐Baptiste, S., Robert, T., Goletto, T., Godet, C., et al. (2023) · Transplant International · doi:10.3389/ti.2023.10841 · Cited by 5
“Other pathologies, n (%) 34 (16) 24 (14) 10 (20) 0.”
MethodFaccioli, E., Verzeletti, V., Giraudo, C., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11061505 · Cited by 5
“PPFE is a pathology with a long subclinical stage [26], and the proper timing to refer a patient to a LT center is still unknown, even though, in most cases, the same criteria used for the referral in the case of IPF are utilized [27,28].”
BackgroundEvaluation of Bone Mineral Density in Lung Transplant Recipients by Chest Computed Tomography
Mori, R., Handa, T., Ohsumi, A., Ikezoe, K., Tanizawa, K., Uozumi, R., Tanabe, N., Oguma, T., Sakamoto, R., Hamaji, M., et al. (2023) · Respiration · doi:10.1159/000535269 · Cited by 6
Disparities in lung transplantation in children
Brugha, R. E., Wu, D., Spencer, H., & Marson, L. (2023) · Pediatric Pulmonology · doi:10.1002/ppul.26813 · Cited by 4
“Early referral where possible is repeatedly stressed in consensus documents, 8 but some of the terminology in these documents is less specific than a clinician may need at the point of decision making; how to define a “ short life expectancy ” or a “ poor quality of life ” ?”
Pathophysiological Insights and Clinical Management Strategies for Interstitial Lung Diseases
Tian, L., Wang, Y., Qi, W., Wang, B., Zhang, X., Gong, M., Zhang, X., & Wang, T. (2025) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2025.004 · Cited by 5
Detection and Evaluation of Drug-associated Pulmonary Arterial Hypertension
Jambon-Barbara, C., Hlavaty, A., Grynblat, J., Antigny, F., Chaumais, M., Humbert, M. J. C., Cracowski, J., Montani, D., & Khouri, C. (2025) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202411-2339pp · Cited by 5
Movement therapy in lung transplantation candidates assisted by a lightweight wearable robot
Just, I. A., Fries, D., Loewe, S., Falk, V., Cesarovic, N., Kemper, D., Edelmann, F., Feuerstein, A., Haufe, F. L., Xiloyannis, M., et al. (2022) · Assistive Technology · doi:10.1080/10400435.2022.2067914 · Cited by 5
“…main contraindications for lung transplantation, roboticassisted training represents a new, innovative approach in the treatment of advanced lung disease-related deconditioning accompanied by a decrease in skeletal muscle mass and tone causing functional instability of joints (Leard et al., 2021).”
BackgroundManaging pulmonary arterial hypertension: how to select and facilitate successful transplantation
Khangoora, V. S., King, C. S., & Shlobin, O. A. (2022) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0000000000000980 · Cited by 5
Self-citationA Conceptual Model for Sources of Differential Selection in Lung Transplant Allocation
Schnellinger, E. M., Cantu, E., Kimmel, S. E., & Szymczak, J. E. (2022) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202202-105oc · Cited by 5
Exercise and Airway Clearance Techniques in Cystic Fibrosis
Ward, N., Stiller, K. R., & Holland, A. E. (2022) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0042-1758729 · Cited by 5
Current best clinical practices for monitoring of interstitial lung disease
Bendstrup, E. M., Kronborg-White, S. B., Møller, J., & Prior, T. S. (2022) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2022.2162504 · Cited by 5
“ILDs progressing despite treatment in inflammatory ILDs, low or significantly decreasing FVC and DLCO over 2 years and oxygen requirement [123].”
Backgroundde Miguel‐Díez, J., Jiménez‐García, R., Hernández‐Barrera, V., Carabantes-Alarcón, D., Zamorano‐León, J. J., Cuadrado‐Corrales, N., Omaña-Palanco, R., González‐Barcala, F. J., & López‐de‐Andrés, A. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12030963 · Cited by 5
“This trend reflects the expansion of acceptable donors and candidates, made possible by clinical and scientific advances [23].”
BackgroundJohnson, B., Dobkin, S. L., & Josephson, M. B. (2022) · Paediatric Respiratory Reviews · doi:10.1016/j.prrv.2022.11.001 · Cited by 5
Alhamdan, F., Coppolino, A., Sheikh, A., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251910562 · Cited by 4
“Lung transplantation is the only curative treatment for severe end-stage pulmonary diseases, such as interstitial lung disease (ILD), chronic obstructive pulmonary disorder (COPD), pulmonary arterial hypertension, and cystic fibrosis, among others [1].”
BackgroundMethodInfluentialLong-Term Macrolides in Chronic Respiratory Diseases: Dusk or a New Dawn? A Narrative Review
Previtero, D., Castelli, G., Padrin, Y., Santello, V., Mengato, D., Biondini, D., Turato, G., Tinè, M., Spagnolo, P., & Semenzato, U. (2025) · Antibiotics · doi:10.3390/antibiotics14111061 · Cited by 6
“Lung transplantation (LTx) is a recognized treatment for end-stage lung diseases, but its long-term success is often undermined by CLAD—a progressive decline in lung function that affects nearly 50% of patients by 5 years and is associated with high mortality [102–104].”
Kaniuk, J. K., Miyashita, Y., Kamar, A., et al. (2025) · Journal of Artificial Organs · doi:10.1007/s10047-025-01529-4 · Cited by 4
A Perspective on Referral and Selection for Pediatric Lung Transplantation
Hayes, D., Avdimiretz, N., Brugha, R. E., Mullen, M. P., Paraskeva, M. A., Mıdyat, L., Solomon, M. P., Sweet, S. C., Melicoff, E., Danziger‐Isakov, L. A., et al. (2025) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2025.08.004 · Cited by 4
Self-citationPharmacological management of connective tissue disease-associated pulmonary arterial hypertension
Kularatne, M., Boucly, A., Savale, L., Solinas, S., Cheron, C., Roche, A., Jevnikar, M., Jaïs, X., Montani, D., Humbert, M. J. C., et al. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2273395 · Cited by 4
“While not a contraindication for transplantation, the presence of connective tissue disease poses a risk factor associated with unfavorable outcomes after lung transplant [114].”
BackgroundKania, K., Wόjcik, K., Czekajewska, J., Grzesiak, M., & Klesiewicz, K. (2023) · Polish Journal of Microbiology · doi:10.33073/pjm-2023-048 · Cited by 5
“Furthermore, M. abscessus is also considered to be a high-risk factor for transplant failure (Kavaliunaite et al. 2020; Leard et al. 2021).”
BackgroundPugashetti, J. V., Kim, J. S., Combs, M. P., Ma, S., Adegunsoye, A., Linderholm, A., Strek, M. E., Chen, C., Dilling, D. F., Whelan, T. P. M., et al. (2024) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2024.03.018 · Cited by 4
Lung transplantation in children
Ehrsam, J. P. (2024) · Turkish Journal of Thoracic and Cardiovascular Surgery · doi:10.5606/tgkdc.dergisi.2024.25806 · Cited by 4
“[47] In the context of PH, the timing of listing for transplantation poses a challenge.”
BackgroundInfluentialCurrent challenges in lung transplantation
Niroomand, A., & Lindstedt, S. (2025) · Journal of Internal Medicine · doi:10.1111/joim.20072 · Cited by 4
“The consensus from ISHLT ultimately is that patients bridged on ECMO should be awake and mobilized for optimal results [63].”
Lung transplant: A clinical overview
Khatana, U. F., Parmar, J. S., & Patterson, C. M. (2025) · Clinical Medicine · doi:10.1016/j.clinme.2025.100328 · Cited by 4
Self-citationParticipation and Progression of Hybrid Rehabilitation following Lung Transplantation
Carson, R., Cordi, C., Campisi, E. S., Moss, S., Trask, A., Zhu, K., Gottesman, C., Ferreira, M. D. P., de Mori, T. A., & Wickerson, L. M. (2025) · Clinical Transplantation · doi:10.1111/ctr.70185 · Cited by 4
Begic, M., Hillebrand, C., Frommlet, F., Benazzo, A., Schweiger, T., Kovacs, Z., Muraközy, G., Jaksch, P., Höetzenecker, K., & Schwarz, S. (2025) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2025.07.005 · Cited by 4
Transplantation pulmonaire en France : actualisation des indications et contre-indications en 2022
Pavec, J. L., Pison, C. M., Hirschi, S., Bunel, V., Mordant, P., Brugière, O., Guen, M. L., Olland, A., Coiffard, B., Renaud-Picard, B., et al. (2022) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2022.10.005 · Cited by 5
de la Hoz, R. E., & Johannson, K. A. (2023) · Archives of Environmental & Occupational Health · doi:10.1080/19338244.2023.2166007 · Cited by 4
“As disease progresses, some patients may be eligible for lung transplantation.(20) Optimal timing for referral varies, but a forced vital capacity < 80%, diffusion capacity < 40%, supplemental oxygen requirement, failure to respond to pharmacotherapy, or diagnoses of IPF or fibrotic nonspecific interstitial pneumoniti…”
BackgroundChen, M., Zou, X., Nan, J., Nuerdawulieti, B., Huxitaer, X., & Jiang, Y. (2023) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph20054599 · Cited by 4
“The ISHLT guidelines have suggested that lung transplantation referral is a complex process and a worldwide challenge [7].”
BackgroundThe Many Hosts of Mycobacteria 9 (MHM9): A conference report
Klever, A. M., Alexander, K. A., Almeida, D. V., Anderson, M. Z., Ball, R. L., Beamer, G., Boggiatto, P. M., Buikstra, J. E., Chandler, B., Claeys, T. A., et al. (2023) · Tuberculosis · doi:10.1016/j.tube.2023.102377 · Cited by 5
Hu, X., Ding, N., Songchen, W., Wang, R., Chen, J., Zhong, A., Nan, J., Zuo, Y., Huang, H., & Tian, D. (2023) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd10080350 · Cited by 7
“Once the clinical condition deteriorates, the LTx listing can be performed in a timely manner [11,38,61,72].”
BackgroundInfluentialBansal, S., Arjuna, A., Franz, B. J., Guerrero-Alba, A., Canez, J., Fleming, T. P., Rahman, M. A., Hachem, R. R., & Mohanakumar, T. (2023) · Frontiers in Transplantation · doi:10.3389/frtra.2023.1248987 · Cited by 3
A narrative review on the management of patients awaiting lung transplantation in Japan
Suzuki, H., & Yoshino, I. (2023) · Journal of Thoracic Disease · doi:10.21037/jtd-22-1690 · Cited by 4
“Due to the extremely long waiting time, earlier registration may be necessary in considering disease progression and age, rather than the timing of registration presented internationally (6).”
Risk factors and clinical consequences of early extubation failure in lung transplant recipients
Chapin, K. C., Dragnich, A. G., Gannon, W. D., et al. (2023) · JHLT Open · doi:10.1016/j.jhlto.2023.100046 · Cited by 4
“Short-term outcomes associated with extubation failure are presented in Table 3; extubation failure was associated with increased ICU LOS [14 days (IQR 10-26) vs 4 days (IQR 4-Figure”
Interstitial lung disease as an indication for pediatric lung transplant
Kuklinski, C. A., & Blatter, J. A. (2023) · Pediatric Pulmonology · doi:10.1002/ppul.26812 · Cited by 4
“31 It is also important to assess the possibility that a patient's primary disease could recur in an allograft.”
Tao, H., Lv, Q., Zhang, J., Chen, L., Yang, Y., & Sun, W. (2024) · Stem Cells International · doi:10.1155/2024/3429565 · Cited by 4
“However, lung trans-plants continue to face signi fi cant clinical constraints, primarily due to the shortage of available donors [114].”
BackgroundInterstitial lung disease in autoimmune diseases
Nagaraja, V., Mira-Avendano, I. C., VERGARA, A. D. A., Gotway, M. B., & Zamora, A. (2024) · Revista Colombiana de Reumatología · doi:10.1016/j.rcreu.2023.12.004 · Cited by 4
Benden, C., & Wikenheiser‐Brokamp, K. A. (2024) · Pediatric Transplantation · doi:10.1111/petr.14739 · Cited by 4
Review of Pulmonary Manifestations in Antisynthetase Syndrome
Ghanbar, M., & Danoff, S. K. (2024) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0044-1785536 · Cited by 12
Guidot, D. M., Wood, M., Poehlein, E., Palmer, S. M., & McElroy, L. M. (2024) · JHLT Open · doi:10.1016/j.jhlto.2024.100121 · Cited by 4
Risk factors for mid- and long-term mortality in lung transplant recipients aged 70 years and older
Pan, Y., Shi, J. T., Li, X., Luo, X., Zhang, J., Luo, C., Lin, Y., Huang, F., He, W., Lan, X., et al. (2024) · Interdisciplinary CardioVascular and Thoracic Surgery · doi:10.1093/icvts/ivae117 · Cited by 4
Profile of patients referred for lung transplant and their transplant-free survival
Rathi, V., Tiwari, P., Seth, S., Hadda, V., Madan, K., Agarwal, S., Vij, A., Hote, M. P., Sahu, M., Mittal, S., et al. (2024) · Lung India · doi:10.4103/lungindia.lungindia_515_23 · Cited by 4
Burdis, N., Kapnadak, S. G., Bartlett, L., McElvaney, O. J., Milinic, T., Wai, T. H., Lange, A. V., Reid, N., Dunitz, J., Billings, J. L., et al. (2024) · BMC Pulmonary Medicine · doi:10.1186/s12890-024-03163-x · Cited by 4
Self-citationImpact of donor age ≥65 years on graft survival in large lung transplant cohorts
Darie, A. M., Levvey, B. J., Shingles, H. V., et al. (2024) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2024.11.002 · Cited by 4
Lung transplantation and bone health: A narrative review
Rzepka, A. M., Tile, L., Chow, C., McDonald-Blumer, H., Chaparro, C., Ridout, R., & Cheung, A. M. (2025) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2025.01.010 · Cited by 4
Lung transplantation for pulmonary chronic graft-versus-host disease: a missed opportunity?
Zajacová, A., Schoemans, H. M., Greer, M., Greinix, H., Jaksch, P., Shtraichman, O., Abdulqawi, R., Holm, A. M., Vos, R., & Bos, S. (2025) · JHLT Open · doi:10.1016/j.jhlto.2025.100209 · Cited by 4
“59 It is important to emphasize that not all neoplastic diseases carry equal risk in the context of LuTx.”
Self-citationGrins, E., Wijk, J., Bjursten, H., Zeaiter, M. C., Lindstedt, S., Dellgren, G., Ederoth, P., & Lannemyr, L. (2025) · Acta Anaesthesiologica Scandinavica · doi:10.1111/aas.70014 · Cited by 5
Self-citationAlamami, A. A. (2025) · The Journal of Critical Care Medicine · doi:10.2478/jccm-2025-0013 · Cited by 4
“Contrain-dications for lung transplantation in ILD patients may include age >65 years, BMI >35 or 16 kg/m², severe coronary artery disease, lack of stable social support, severe esophageal motility disorder, or significant psychological illness [24, 25].”
Exacerbation of chronic renal failure because of inhaled tobramycin in a lung transplant patient
Cuesta, V. M. M., Vargas, N. B., Fernandez, D. I., Mena, S. T., & Martínez, J. M. C. (2022) · Respiratory Medicine Case Reports · doi:10.1016/j.rmcr.2022.101584 · Cited by 4
A Delphi consensus statement for the management of post-COVID interstitial lung disease
Hadda, V., Suri, T. M., Iyer, H. K., Jain, A., Mittal, S., Madan, K., Mohan, A., Bhalla, A. S., Sindhwani, G., Dutt, N., et al. (2022) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2022.2128770 · Cited by 4
“General contraindications for lung transplantation as recommended by the International Society of Heart and Lung Transplantation (ISHLT) also apply to patients with postCOVID ILD [81].”
BackgroundSymptoms and disease severity in lung transplant candidates co-managed with palliative care
Minuk, L., Chohan, K., Kumbhare, D. A., Reid, W. D., Wentlandt, K., & Rozenberg, D. (2023) · Annals of Palliative Medicine · doi:10.21037/apm-22-905 · Cited by 4
Predicting outcomes in lung transplantation: From tea leaves to ChatGPT
Rozenberg, D., & Singer, L. G. (2023) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2023.03.019 · Cited by 4
A new method for classifying prognostic risk factors in lung transplant candidates
Lehr, C. J., Dalton, J. E., Gunsalus, P. R., Gunzler, D. D., & Valapour, M. (2023) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2023.06.009 · Cited by 5
Self-citationKing, C. S., White, E., Aryal, S., Shlobin, O. A., SINGHAL, A. L., Brown, A. W., Thomas, C., Khangoora, V. S., NYQUIST, A. S., Flaherty, K. R., et al. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e18618 · Cited by 6
Self-citationAggarwal, R., Potel, K. N., Jackson, S., Lemke, N. T., Kelly, R. F., Soule, M., Diaz‐Gutierrez, I., Shumway, S. J., Patil, J., Hertz, M. I., et al. (2023) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2023.09.031 · Cited by 5
Recovery of extracorporeal lungs using cross-circulation with injured recipient swine
Chen, P., Hassel, J. V., Pinezich, M. R., et al. (2023) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2023.09.032 · Cited by 4
“Although we hypothesize that the capability of acutely injured swine to handle the additional demand of extracorporeal lungs can be extrapolated to chronic disease recipients, future work should investigate additional challenges that may be posed by chronic disease models.”
BackgroundOzemek, C., Hardwick, J., Bonikowske, A. R., Christle, J. W., German, C. A., Reddy, S., Arena, R. A., & Faghy, M. A. (2024) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2024.02.014 · Cited by 5
Pulmonary Hypertension in Connective Tissue Diseases Other than Systemic Sclerosis
Budhram, B., Weatherald, J. C., & Humbert, M. J. C. (2024) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0044-1782217 · Cited by 4
Recipient selection, timing of referral, and listing for lung transplantation
Lashari, B. H., Myers, C. N., Brown, J., Galli, J. A., & Sehgal, S. (2022) · Indian Journal of Thoracic and Cardiovascular Surgery · doi:10.1007/s12055-022-01330-5 · Cited by 5
“And as with CF, a low FEV1 has been associated with higher mortality, and an FEV1 < 30% predicted can be associated with a 4-year mortality of up to 39% [30].”
BackgroundInfluentialAdvances in Surgical and Mechanical Management of Chronic Obstructive Pulmonary Disease
Lashari, B. H., & Criner, G. J. (2022) · Medical Clinics of North America · doi:10.1016/j.mcna.2022.07.006 · Cited by 4
Jin, X., Vanluyten, C., Orlitová, M., Slambrouck, J. V., Vos, R., Verleden, G. M., Godinas, L., Neyrinck, A., Ingels, C., Vanaudenaerde, B. M., et al. (2023) · Journal of Thoracic Disease · doi:10.21037/jtd-23-64 · Cited by 3
Lehr, C. J., & Pilewski, J. M. (2022) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0000000000000975 · Cited by 4
Candidate selection for lung transplantation – considerations beyond the medical evidence
Holm, A. M. (2024) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000001084 · Cited by 3
Self-citationThuan, P. Q., Nam, N. H., & Định, N. H. (2024) · SAGE Open Medicine · doi:10.1177/20503121241275410 · Cited by 3
Huang, H. F., Wang, Q., & Xu, Z. (2024) · Therapeutic Advances in Respiratory Disease · doi:10.1177/17534666241288417 · Cited by 4
“80,82 While a number of risk factors are absolute contraindications to lung transplant, such as acute liver or kidney failure, it should be noted that old age is not an absolute contraindication, but older individuals tend to have worse long-term survival post-transplant, and patients should be…”
BackgroundKhan, S. L., Minkove, S. J., Psoter, K. J., Mathai, S. C., Danoff, S. K., & Shah, P. D. (2025) · JHLT Open · doi:10.1016/j.jhlto.2025.100290 · Cited by 4
Therapeutic options for patients with pulmonary hypertension and interstitial lung disease
Swisher, J. W., & Weaver, E. (2025) · Therapeutic Advances in Respiratory Disease · doi:10.1177/17534666251335815 · Cited by 3
Zhu, Q., Gu, P., Wang, Y., Zeng, F., & Lan, M. (2025) · International Journal of Nursing Studies · doi:10.1016/j.ijnurstu.2025.105160 · Cited by 3
Toporek, A. H., Adjei, E., Gannon, W. D., Stokes, J., Demarest, C. T., Bacchetta, M. D., Höetzenecker, K., & Trindade, A. J. (2025) · JHLT Open · doi:10.1016/j.jhlto.2025.100368 · Cited by 4
Calabrese, F., Pezzuto, F., Vedovelli, L., Chellis, C. D., Lunardi, F., Loy, M., Faccioli, E., Vadori, M., Biondini, D., Marinello, S., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1619771 · Cited by 3
Management of Lung Manifestations in Idiopathic Inflammatory Myopathies
Krishnan, A., Jain, S., & Lammi, M. R. (2025) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2025.07.007 · Cited by 3
Pretransplant screening for infections in lung and heart transplant candidates
Riunga, F., Cervera, C., & Kabbani, D. (2025) · JHLT Open · doi:10.1016/j.jhlto.2025.100409 · Cited by 3
“Screening practices for lung and heart transplant (LTx and HTx) candidates are broadly framed around these categories 3,6,7 and summarized in Tables 1 and 2, Figure 1.”
Olanipekun, T. O., Divo, M. J., ABE, T., Tadesse, A., Poli, S., Jacob, S., Sheikh, A., & Sharma, N. (2026) · European Respiratory Review · doi:10.1183/16000617.0018-2025 · Cited by 3
Cuesta, V. M. M., Meñaca, A. M., Fernandez, D. I., et al. (2023) · Archivos de Bronconeumología · doi:10.1016/j.arbres.2022.12.016 · Cited by 3
Piotrowska, M., Wojtyś, M. E., Kiełbowski, K., Bielewicz, M., Wasilewski, P., Safranow, K., Grodzki, T., & Kubisa, B. (2023) · Pathogens · doi:10.3390/pathogens12020306 · Cited by 3
“In addition, more than 80% probability of surviving for the next five years after the procedure are required, considering the proper function of the graft [3].”
BackgroundHematopoietic Stem Cells Transplant (HSCT)-Related Chronic Pulmonary Diseases: An Overview
Traunero, A., Peri, F., Badina, L., Amaddeo, A., Zuliani, E., Maschio, M., Barbi, E., & Ghirardo, S. (2023) · Children · doi:10.3390/children10091535 · Cited by 4
“The current international guidelines [59] establish that there must be a time interval of more than 5 years between HSCT and LT for patients with a history of hematologic malignancy.”
BackgroundFrailty as a Prognostic Indicator in Lung Transplantation: A Comprehensive Analysis
Hage, R., & Schuurmans, M. M. (2023) · Transplantology · doi:10.3390/transplantology5010001 · Cited by 4
“…for Heart and Lung Transplantation (ISHLT) consensus document for the selection of lung transplant candidates emphasizes that individuals with limited functional status and poor potential for post-transplant rehabilitation are considered absolute contraindications for lung transplantation [19].”
Analysis of Primary Graft Dysfunction (PGD) Risk Factors in Lung Transplantation (LuTx) Patients
Kubisa, M. J., Wojtyś, M. E., Lisowski, P., Kordykiewicz, D., Piotrowska, M., Wójcik, J., Pieróg, J., Safranow, K., Grodzki, T., & Kubisa, B. (2024) · Clinics and Practice · doi:10.3390/clinpract14040127 · Cited by 3
“There are specific qualification criteria and particular disease indications required to put patients on a waiting list for LuTx [2].”
BackgroundManagement erwachsener Patientinnen und Patienten mit Bronchiektasen-Erkrankung
Ringshausen, F. C., Baumann, I. G., Roux, A. D., Dettmer, S., Diel, R., Eichinger, M., Ewig, S., Flick, H., Hanitsch, L. G., Hillmann, T., et al. (2024) · Pneumologie · doi:10.1055/a-2311-9450 · Cited by 4
Lung transplant outcomes in recipients of advanced age: Are two always better than one?
Shacker, M., Roy, S. B., Arjuna, A., Schaheen, L. W., Walia, R., Bremner, R. M., & Smith, M. A. (2024) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2024.11.035 · Cited by 4
Lung transplantation — indications, follow-up care and long-term results
Michel, S. G., Schneider, C., Ius, F., Welte, T., Gottlieb, J., & Kneidinger, N. (2025) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.m2024.0232 · Cited by 4
Metadata
- Authors
- Leard, L. E., Holm, A. M., Valapour, M., Glanville, A. R., Attawar, S., Aversa, M., Campos, S. V., Christon, L. M., Cypel, M., Dellgren, G., Hartwig, M. G., Kapnadak, S. G., Kolaitis, N. A., Kotloff, R. M., Patterson, C. M., Shlobin, O. A., Smith, P. J., Solé, A., Solomon, M., Weill, D., Wijsenbeek, M. S., Willemse, B. W. M., Arcasoy, S. M., & Ramos, K. J.
- Affiliations
- University of California, San Francisco (US)
- Oslo University Hospital (NO)
- Cleveland Clinic (US)
- St Vincent's Hospital Sydney (AU)
- Krishna Institute of Medical Sciences (IN)
- University of Toronto (CA)
- Medical University of South Carolina (US)
- Sahlgrenska University Hospital (SE)
- Duke University (US)
- University of Washington (US)
- University of Pennsylvania (US)
- Royal Papworth Hospital (GB)
- Inova Fairfax Hospital (US)
- Erasmus MC (NL)
- University Medical Center Groningen (NL)
- Columbia University (US)
- Corresponding author
- Leard, Lorriana E.
- ORCID
- Leard, Lorriana E.
- Holm, Are M.
- Valapour, Maryam
- Glanville, Allan R.
- Attawar, Sandeep
- Aversa, Meghan
- Christon, Lillian M.
- Cypel, Marcelo
- Dellgren, Göran
- Hartwig, Matthew G.
- Kapnadak, Siddhartha G.
- Kolaitis, Nicholas A.
- Patterson, Caroline M.
- Shlobin, Oksana A.
- Smith, Patrick J.
- Solomon, Melinda
- Wijsenbeek, Marlies S.
- Willemse, Brigitte W.M.
- Arcasoy, Selim M.
- Ramos, Kathleen J.
- Venue
- The Journal of Heart and Lung Transplantation
- Publisher
- Elsevier BV
- Published
- 2021-11
- Volume
- 40
- Issue
- 11
- Pages
- 1349-1379
- ISSN
- 1053-2498 (ISSN-L)
- PMC
- PMC8979471
- OpenAlex
- W3183806681
- Semantic Scholar
- 428c0f28db10a88c62c6b907d2c92a02bac6b503
- Cited by
- 821
- References
- 363
- Citations by year
- 2026: 170 · 2025: 181 · 2024: 186 · 2023: 176 · 2022: 97 · 2021: 11
- FWCI
- 110.28
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Heart and Lung Transplantation (publishedVersion, cc-by)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion, cc-by)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion, cc-by)
- PubMed Central (acceptedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, other-oa)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, cc-by)
- Funders
- U.S. Department of Health and Human Services
- Cystic Fibrosis Foundation
- Boomer Esiason Foundation
- Bristol-Myers Squibb
- United Therapeutics Corporation
- European Respiratory Society
- Vertex Pharmaceuticals
- Savara Pharmaceuticals
- Galecto
- ZonMw
- Astellas Pharma
- Lung Foundation Netherlands
- National Institutes of Health
- Health Resources and Services Administration
- National Heart, Lung, and Blood Institute (K23HL138154)
- Topics
- Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Organ Donation and Transplantation
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- lung transplantation, transplant candidate selection, advanced lung disease, referral timing, transplant evaluation, transplant listing, transplant ethics, risk stratification, International Society for Heart and Lung Transplantation
- MeSH terms
- Contraindications, Cystic Fibrosis, Humans, Societies, Medical, Lung Transplantation, Patient Selection, Pulmonary Disease, Chronic Obstructive
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-09-25 (prompt extract-v2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
